Is type III prostatitis also associated with bacterial infection?
16s rRNA sequencing technique
chronic prostatitis
expressed prostatic secretion
metagenomics
microbiology
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
04
2023
accepted:
16
06
2023
medline:
21
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
To explore whether type III prostatitis is related to bacterial infection by detecting the composition and function of microorganisms in expressed prostatic secretion (EPS) of patients with chronic prostatitis (CP) and healthy people. According to the inclusion and exclusion criteria, 57 subjects were included in our study, divided into the healthy group, type II prostatitis group, and type III prostatitis group. 16s rRNA sequencing technique was used to detect and analyze the microbial composition of EPS in each group. Additionally, the metagenomics sequencing technique was used to further explore the function of different bacteria in the type III prostatitis group. Data analysis was performed by bioinformatics software, and the results were statistically significant when P<0.05. Many microorganisms exist in EPS in both CP patients and healthy populations. However, the relative abundance of Based on our sequencing results and previous studies, we suggest that type III prostatitis may also be caused by bacterial infection.
Identifiants
pubmed: 37465760
doi: 10.3389/fcimb.2023.1189081
pmc: PMC10351278
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1189081Informations de copyright
Copyright © 2023 Song, Gao, Huang, Liu, Long and He.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Antibiot (Tokyo). 2017 Jul;70(7):853-855
pubmed: 28420868
Curr Opin Microbiol. 2007 Oct;10(5):490-8
pubmed: 17936679
Hum Reprod. 2018 Jul 1;33(7):1212-1217
pubmed: 29850857
World J Mens Health. 2015 Aug;33(2):103-8
pubmed: 26331127
Infect Agent Cancer. 2016 Jun 09;11:26
pubmed: 27284286
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Chemother. 2002 Oct;14(5):537-8
pubmed: 12462437
Gigascience. 2013 Nov 26;2(1):16
pubmed: 24280061
Biomedicines. 2021 Apr 15;9(4):
pubmed: 33921011
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
JAMA. 1999 Jul 21;282(3):236-7
pubmed: 10422990
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(2):25-9
pubmed: 26086164
Res Microbiol. 2021 Jun-Aug;172(4-5):103834
pubmed: 33894336
Chembiochem. 2013 Jun 17;14(9):1085-93
pubmed: 23677853
Iran J Pathol. 2016 Spring;11(2):138-43
pubmed: 27499775
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Eur Urol. 2017 Oct;72(4):625-631
pubmed: 28434677
AMB Express. 2022 Nov 3;12(1):138
pubmed: 36327024
Cochrane Database Syst Rev. 2019 Oct 06;10:CD012552
pubmed: 31587256
Microb Ecol Health Dis. 2015 May 29;26:27663
pubmed: 26028277
Cureus. 2022 Mar 28;14(3):e23583
pubmed: 35495004
Ann Transl Med. 2017 Jan;5(2):30
pubmed: 28217695
Front Microbiol. 2020 Jan 20;10:3141
pubmed: 32038574
BMC Genomics. 2019 Feb 18;20(1):146
pubmed: 30777011